Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Across the Spectrum of Hypertension

被引：16

作者：

Sanidas, Elias A. ^{[1
]}

Papadopoulos, Dimitrios P. ^{[1
]}

Hatziagelaki, Erifili ^{[2
]}

Grassos, Charalampos ^{[3
]}

Velliou, Maria ^{[1
]}

Barbetseas, John ^{[1
]}

机构：

[1] Laikon Gen Hosp, Dept Cardiol, Hypertens Excellence Ctr ESH, Athens, Greece

[2] Athens Med Sch, Attikon Gen Hosp, Dept Internal Med 2, Athens, Greece

[3] KAT Gen Hosp, Hypertens Excellence Ctr ESH, Dept Cardiol, Athens, Greece

来源：

AMERICAN JOURNAL OF HYPERTENSION | 2020年 / 33卷 / 03期

关键词：

arterial hypertension; blood pressure; diabetes mellitus; SGLT-2; Inhibitors; TYPE-2; DIABETES-MELLITUS; BLOOD-PRESSURE; EMPAGLIFLOZIN; DAPAGLIFLOZIN; CANAGLIFLOZIN; REDUCTION; SAFETY; IMPACT; RHYTHM;

D O I：

10.1093/ajh/hpz157

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Sodium glucose cotransporter 2 (SGLT2) inhibitors represent a novel class of oral antihyperglycemic drugs that have been approved over the last decade for the management of type 2 diabetes mellitus. Except the glucose-lowering effects, robust evidence also suggests that SGLT2 inhibitors confer benefits in cardiovascular system. The purpose of this review was to investigate the effects of SGLT2 inhibitors across the spectrum of arterial hypertension.

引用

页码：207 / 213

页数：7

共 37 条

[11] Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial [J].

Han, Kyung-Ah ;

Chon, Suk ;

Chung, Choon Hee ;

Lim, Soo ;

Lee, Kwan-Woo ;

Baik, SeiHyun ;

Jung, Chang Hee ;

Kim, Dong-Sun ;

Park, Kyong Soo ;

Yoon, Kun-Ho ;

Lee, In-Kyu ;

Cha, Bong-Soo ;

Sakatani, Taishi ;

Park, Sumi ;

Lee, Moon-Kyu .

DIABETES OBESITY & METABOLISM, 2018, 20 (10) :2408-2415

[12] An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus [J].

Hsia, Daniel S. ;

Grove, Owen ;

Cefalu, William T. .

CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2017, 24 (01) :73-79

[13] Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension Results From the Randomized, Placebo-Controlled SACRA Study [J].

Kario, Kazuomi ;

Okada, Kenta ;

Kato, Mitsutoshi ;

Nishizawa, Masafumi ;

Yoshida, Tetsuro ;

Asano, Tsuguyoshi ;

Uchiyama, Kazuaki ;

Niijima, Yawara ;

Katsuya, Tomohiro ;

Urata, Hidenori ;

Osuga, Jun-ichi ;

Fujiwara, Takeshi ;

Yamazaki, Shoji ;

Tomitani, Naoko ;

Kanegae, Hiroshi .

CIRCULATION, 2019, 139 (18) :2089-2097

[14] Importance of inhibiting sodium-glucose cotransporter and its compelling indication in type 2 diabetes: pathophysiological hypothesis [J].

Kimura, Genjiro .

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2016, 10 (03) :271-278

[15] Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis [J].

Liakos, A. ;

Karagiannis, T. ;

Athanasiadou, E. ;

Sarigianni, M. ;

Mainou, M. ;

Papatheodorou, K. ;

Bekiari, E. ;

Tsapas, A. .

DIABETES OBESITY & METABOLISM, 2014, 16 (10) :984-993

[16] SGLT2 inhibitors: their potential reduction in blood pressure [J].

Maliha, George ;

Townsend, Raymond R. .

JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2015, 9 (01) :48-53

[17] Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication [J].

Mancia, Giuseppe ;

Cannon, Christopher P. ;

Tikkanen, Ilkka ;

Zeller, Cordula ;

Ley, Ludwin ;

Woerle, Hans J. ;

Broedl, Uli C. ;

Johansen, Odd Erik .

HYPERTENSION, 2016, 68 (06) :1355-1364

[18] Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients [J].

Mazidi, Mohsen ;

Rezaie, Peyman ;

Gao, Hong-Kai ;

Kengne, Andre Pascal .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2017, 6 (06)

[19] The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics [J].

McMurray, John J. V. ;

DeMets, David L. ;

Inzucchi, Silvio E. ;

Kober, Lars ;

Kosiborod, Mikhail N. ;

Langkilde, Anna Maria ;

Martinez, Felipe A. ;

Bengtsson, Olof ;

Ponikowski, Piotr ;

Sabatine, Marc S. ;

Sjostrand, Mikaela ;

Solomon, Scott D. .

EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 (11) :1402-1411

[20] A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF) [J].

McMurray, John J., V ;